MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$10,131,000
Net Income
-$40,622,000
Net Profit Margin
-400.97%
EPS
-$1.23
Unit: Dollar
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
10,131,000
10,861,000
20,784,500*
11,790,000
Cost of goods sold
-
-
0*
0
Research and development (including 1,137 and 613 for the three months ended june 30, 2026 and 2025, respectively, from a related party and 2,845 and 821 for the six months ended june 30, 2026 and 2025, respectively, from a related party)
39,129,000
35,680,000
31,623,000*
27,252,000
General and administrative
12,765,000
13,439,000
18,960,000*
16,070,000
Restructuring and impairment
578,000
796,000
8,450,500*
140,000
Gain on sale of the huntsville manufacturing facility
-
-
0*
-
Total operating costs and expenses
52,472,000
49,915,000
59,033,500*
43,462,000
Loss from operations
-42,341,000
-39,054,000
-38,249,000*
-31,672,000
Non-cash interest expense on liabilities related to the sales of future royalties
7,206,000
7,942,000
9,022,500*
6,047,000
Interest income
9,346,000
4,242,000
3,256,000*
2,819,000
Other income (expense), net (including income of 0 and 540 for the three months ended june 30, 2026 and 2025, respectively, from a related party and income of 2 and 861 for the six months ended june 30, 2026 and 2025, respectively, from a related party)
-100,000
-336,000
152,500*
-121,000
Total non-operating income (expense), net
2,040,000
-4,036,000
-5,614,000*
-3,349,000
Loss before provision (benefit) for income taxes and equity method investment
-40,301,000
-43,090,000
-43,863,000*
-35,021,000
Provision (benefit) for income taxes
2,000
64,000
193,500*
-33,000
Loss before equity method investment
-40,303,000
-43,154,000
-44,056,500*
-34,988,000
Loss from equity method investment
-319,000
-1,750,000
-4,347,000*
-534,000
Net loss
-40,622,000
-44,904,000
-48,403,500
-35,522,000
Basic EPS
-1.23
-1.82
-2.753
-1.87
Diluted EPS
-1.23
-1.82
-2.753
-1.87
Basic Average Shares
33,054,865
24,736,066
17,578,924
18,946,559
Diluted Average Shares
33,054,865
24,736,066
17,578,924
18,946,559
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss-$40,622,000 (2.33%↑ Y/Y)Loss before equitymethod investment-$40,303,000 (-2.80%↓ Y/Y)Loss from equitymethod investment-$319,000 (86.63%↑ Y/Y)Interest income$9,346,000 (374.66%↑ Y/Y)Loss beforeprovision (benefit) for...-$40,301,000 (-2.30%↓ Y/Y)Provision (benefit) forincome taxes$2,000 (101.06%↑ Y/Y)Total non-operatingincome (expense), net$2,040,000 (164.45%↑ Y/Y)Non-cash interestexpense on liabilities...$7,206,000 (33.59%↑ Y/Y)Other income(expense), net (including...-$100,000 (-138.46%↓ Y/Y)Loss from operations-$42,341,000 (-16.87%↓ Y/Y)Total revenue$10,131,000 (-9.34%↓ Y/Y)Total operating costsand expenses$52,472,000 (10.69%↑ Y/Y)Research and development(including 1,137 and 613 for...$39,129,000 (30.93%↑ Y/Y)General andadministrative$12,765,000 (-25.23%↓ Y/Y)Restructuring and impairment$578,000 (29.31%↑ Y/Y)

NEKTAR THERAPEUTICS (NKTR)

NEKTAR THERAPEUTICS (NKTR)